Non-Invasive Prenatal Testing (NIPT) is a screening test performed using a maternal blood sample from the 9th week of pregnancy onward. It analyzes cell-free fetal DNA (cfDNA) released from the placenta into the maternal bloodstream to screen for chromosomal abnormalities.
Unlike conventional count-based NIPT assays, this test distinguishes fetal DNA from maternal DNA. By combining the NGS method with the Massively Parallel Sequencing (MPS) principle, it minimizes technical errors, reduces false-positive rates, and provides more reliable interpretation of results, particularly for sex chromosome aneuploidies and complex pregnancies.
With more than a decade of clinical use, this test offers several distinguishing features, including the ability to differentiate maternal X chromosome mosaicism, detect triploidy, and report results for the viable fetus in pregnancies complicated by a vanishing twin.
Please contact our center for detailed information about the available test options and panel coverage.
Panel selection is determined based on the clinical characteristics of the pregnancy, ultrasound findings, family history, and the physician’s clinical evaluation.
After sample collection at our laboratory, NIPT samples are sent to an authorized reference laboratory in the United States for analysis.
NIPT is a screening test. Positive or high-risk results must be confirmed using invasive prenatal diagnostic procedures, such as chorionic villus sampling (CVS) or amniocentesis (see: Prenatal Testing).
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, Şişli / Istanbul
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
The content provided on this site is intended for informational purposes only and is not a substitute for professional medical advice or diagnosis. Always seek the advice of a qualified healthcare provider for any medical evaluation, diagnosis, or treatment.
All rights reserved © 2026. Explicit Consent Statement | Last Updated: 27.04.2026 14:00 / mowaffak@hotmail.com
